This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DMK DMK Pharmaceuticals (DMK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About DMK Pharmaceuticals Stock (NASDAQ:DMK) 30 days 90 days 365 days Advanced Chart Get DMK Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.04▼$0.5852-Week Range N/AVolume24.16 million shsAverage Volume1.16 million shsMarket Capitalization$2.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. Read More Receive DMK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DMK Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DMK Stock News HeadlinesTrump says pharmaceutical tariffs could reach 200%July 10, 2025 | msn.comCompounding Company Executive Convicted Of Conspiracy In Drug Kickback SchemeJuly 3, 2025 | msn.comTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trillions in oil, gas, lithium, and land rights. Whitney Tilson breaks it all down, and shows how everyday Americans can grab a stake. His urgent new briefing explains "The US: IPO"... and how to get in before the looming federal deadline.July 28 at 2:00 AM | Stansberry Research (Ad)Arla and DMK unlikely to be last big deal in Europe’s stagnant dairy marketApril 14, 2025 | msn.comDenmark's Arla plans dairy tie-up with Germany's DMKApril 9, 2025 | reuters.comArla and DMK to merge into European dairy heavyweightApril 8, 2025 | msn.comSEC hits ex-pharma CFO with sanction over fraud chargesJanuary 16, 2025 | finance.yahoo.comAdamis Pharmaceuticals Corp (CY3.MU)September 21, 2024 | nz.finance.yahoo.comSee More Headlines DMK Stock Analysis - Frequently Asked Questions What other stocks do shareholders of DMK Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that DMK Pharmaceuticals investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Sangamo Therapeutics (SGMO) and Bakkt (BKKT). Company Calendar Today7/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DMK CIK887247 Webwww.dmkpharmaceuticals.com Phone858-997-2400FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.48 million Net Margins-630.85% Pretax Margin-600.29% Return on EquityN/A Return on Assets-251.02% Debt Debt-to-Equity RatioN/A Current Ratio0.58 Quick Ratio0.54 Sales & Book Value Annual Sales$3.62 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.38) per share Price / BookN/AMiscellaneous Outstanding Shares10,102,000Free Float9,506,000Market Cap$2.34 million OptionableNo Data Beta1.11 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:DMK) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop 10 Green Zone Stocks to Buy NowOthers have paid $2,000 for access to stock picks like these—this weekend, you can get them free. Using a p...TradeSmith | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DMK Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DMK Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.